Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial
recent developmental investment and subsequent drug approvals over the past 6 years. In …

Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

Antibody–drug conjugates (ADCs) constitute a relatively new group of anticancer agents,
whose first appearance took place about two decades ago, but a renewed interest occurred …

Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now
often treated in the newly diagnosed and relapsed and/or refractory settings with …

Emerging evidence indicates that cancer cells can mimic characteristics of embryonic
development, promoting their development and progression. Cancer cells share features …

Antibody drug conjugates (ADCs) have made impressive strides in the clinic in recent years
with 11 Food and Drug Administration approvals, including 6 for the treatment of patients …

In the past, there was no second-line chemotherapeutic agent suitable for use when
urothelial carcinoma (UC) progressed to platinum-resistant UC. However, recently, several …

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that are
involved in the regulation of cell proliferation, survival, and development. FGFR alterations …

Next‑generation sequencing The patient was initially unwilling for an NGS due to financial
constraints. However, as he was heavily pretreated and had exhausted almost all standard …